(NASDAQ: ORGO) Organogenesis Holdings's forecast annual revenue growth rate of 10.51% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.68%.
Organogenesis Holdings's revenue in 2025 is $482,043,000.On average, 1 Wall Street analysts forecast ORGO's revenue for 2025 to be $64,505,021,247, with the lowest ORGO revenue forecast at $64,505,021,247, and the highest ORGO revenue forecast at $64,505,021,247. On average, 1 Wall Street analysts forecast ORGO's revenue for 2026 to be $74,183,399,776, with the lowest ORGO revenue forecast at $74,183,399,776, and the highest ORGO revenue forecast at $74,183,399,776.
In 2027, ORGO is forecast to generate $85,301,784,461 in revenue, with the lowest revenue forecast at $85,301,784,461 and the highest revenue forecast at $85,301,784,461.